News
Presentation of The NGAL Test data at the 30th International Symposium on Intensive Care and Emergency Medicine (ISICEM)
February 22 2010
BioPorto Diagnostics obtains Quality Management Certification
February 18 2010
TSIS 2010, March 9-13, Munich, Germany
February 18 2010
ToxExpo, March 7-11, Salt Lake City, Utah
February 16 2010
CRITICARE 2010, February 10-14, Hyderabad, India
January 25 2010
Congress calendar 2010
January 11 2010
SCCM Annual Congress, January 9-13, Miami Beach, Florida
January 07 2010
BioPorto Diagnostics and ALPCO Diagnostics enter into partnership
December 02 2009
Product launch: Dog NGAL ELISA Kit (KIT 043)
November 16 2009
MEDICA, November 18-21, Düsseldorf, Germany
November 09 2009
BioPorto Diagnostics at the Biomarker World Congress 2009, May 27-29, Philadelphia
May 26 2009 by Ana Belén Enfedaque Buisán
Since the very identification of NGAL as an early marker for kidney injury, BioPorto Diagnostics has offered NGAL assays and antibodies. The value of NGAL as an acute kidney injury marker in humans has gained strong support through widely published scientific literature. Furthermore, NGAL has also proven to be invaluable to the pharmaceutical industry in its use as a marker of nephrotoxicity in experimental animals.
The Biomarker World Congress 2009 addresses both of these market segments for NGAL by spanning the pharmaceutical and diagnostic pipeline in a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, amongst others. The perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
Jakob Ohm Eriksen, NGAL pharma (clinical and preclinical) Product Manager will attend the congress on behalf of BioPorto Diagnostics. Contact him at joe@bioporto.com.
For further information on the event: http://www.biomarkerworldcongress.com/
